Dialog Box


Clinical Trials 

Check out the new Rare Cancers Australia Knowledgebase for more clinical trials that are available here

Clinical trials are an essential part of the development of new treatments and help to improve the diagnosis, treatment and management of people with cancer.

RCA provides information about clinical trial registries and individual clinical trials with the hope that it assists you to be informed about what clinical trials are available. However, RCA is not responsible for the content or maintenance of these sites or specific clinical trial information. We will endeavor to keep this information up to date but the reader is ultimately responsible to check the accuracy of this information.

RCA neither recommends nor endorses any clinical trials. Patients are encouraged to complete their own research into any clinical trials and possible effects and impacts to their health as a result of such trials. It is the patient’s responsibility, in consultation with their medical professional, to determine whether they wish to take part in such trials.
Before you consider participation in any clinical trial you should seek advice from your medical professional. 

Clinical Trial Registries

Clinical trial registries allow you to find clinical trials in Australia. A registry is defined as an organisation or website that either:

  • Lists clinical trials being conducted (or that have recently been conducted) in Australia (or internationally, including Australia)
  • Provides a mechanism for patients or others to register their interest in participating in an Australian clinical trial
  • Provides a link between potential participants and Australian clinical trials.

For Clinical Trial Registries please visit

Other clinical trial registries can be found by visiting these links:

Other Clinical Trials

From time to time RCA is approached by clinicians who are involved with a clinical trial to share relevant information with the patient community. Details of these trials with contact information are below. Further details can be found on the Rare Cancers Australia Knowledgebase

Trial Name: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (NCT02872116)
Locations:    St John of God Murdoch Hospital, WA
                      Gosford Hospital, NSW
                      Royal Adelaide Hospital, SA
                      Goulburn Valley Health, VIC
                      Ballarat Base Hospital, VIC
                      Tasman Oncology Research, QLD
                      Blacktown Hospital, NSW
                      Sunshine Hospital, VIC
Description: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Trial Name: An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (NCT0262409)
Locations:    St John of God Murdoch Hospital, WA
                      Calvary Mater Newcastle, NSW
                      Royal North Shore Hospital, NSW
                      Lyell McEwin Hospital, SA
                      Frankston Hospital, VIC
Description: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma.

Trial Name: The Cancer Molecular Screening and Therapeutics (MoST) Program-Screening. (ACTRN12616000908437)
Location: NHMRC Clinical Trials Centre, Level 6, Chris O'Brien Lifehouse, 119–143 Missenden Road, Camperdown NSW 2050
This study is a collaboration between the Garvan Institute of Medical Research, the Kinghorn Cancer Centre, Sydney Catalyst and the NHMRC Clinical Trials Centre, University of Sydney. The study is currently open at St Vincent’s Hospital in Darlinghurst, and will soon open at Chris O’Brien Lifehouse and St George’s Hospital in Sydney.
      The study is led by Professor David Thomas (Garvan Institute of Medical Research, The Kinghorn Cancer Centre) and Professor John Simes (NHMRC Clinical Trials Centre).
      The explosion in genomic capacity presents the opportunity to molecularly phenotype cancers in unprecedented detail. Genomic screening tools are increasingly used to guide therapeutic decisions for individual patients, yielding the notion of ‘precision’ medicine.  
      The MoST Study uses novel genomics and other molecular assays for therapeutic targets, to identify ‘actionable’ mutations for patients with advanced cancers of any kind, but with a particular focus on rare cancers. The MoST then offers multiple, parallel, signal-seeking trials of novel drugs to patents in whom an ‘actionable’ target is found.
For more details contact

Trial Name: Genetic Cancer Risk in the Young (RISC) Study.
Location: Garvan Institute of Medical Research, remote participation can be arranged
Description: The RISC study is trying to understand more about the hereditary causes of cancer. The study is using whole genome sequencing to look for changes in the DNA code that may increase the risk of developing cancer.
To participate you must have had a cancer diagnosis when you were aged 16-40 years. Participation involves

  • Completing a consent form
  • Completing 3 questionnaires over 12 months
  • Providing a blood sample
  • Allowing access to medical records and archived tissue samples 
  • Inviting interested family members to participate
  • Optional interview
  • Optional biobanking

Contact: For more details contact

Trial Name: UNISoN Trial. (NCT03177239)
Location: Sites in Queensland, South Australia, Victoria, and NSW are active with many more coming online soon
In this clinical trial ANZUP will test whether new immune treatments can help people with rare kidney cancer (‘non-clear cell’ cancer). Non-clear cell represents approximately 25% of people with kidney cancer; and because it is rare there are no treatments currently reimbursed in Australia.
      The UNISoN trial will test immune treatments in two different ways; firstly we will find out how well one immune treatment (nivolumab) works alone. If this is unhelpful by itself, then people can continue taking nivolumab but also add in a 2nd immune treatment (ipilimumab). We will discover how many people will benefit from one drug alone, and by doing detailed laboratory testing of people’s cancer samples, hope to also learn who will only benefit from taking both treatments together.
      Nivolumab and ipilimumab have been used alone or together in many cancers, so the side-effects are well known and should be manageable. Immune treatments help some people with cancer, especially those with melanoma, common (clear cell) kidney cancer, lung and bladder cancer. Unfortunately they are much less effective in other cancers (like pancreas, prostate and brain cancers). Nivolumab and ipilimumab have not been tested in people with non-clear cell kidney cancers, so ANZUP is delighted to ask this question, and hope to help people with this rare disease.
More information can be found here and if you're interested you can print off the UNISoN details from the Australia New Zealand Clinical Trials Registry and take it to your GP. 

Trial Name: PRISM: Precision Medicine for Children with Cancer (NCT03336931)
Location:   John Hunter Children's Hospital, Newcastle, NSW
                   Sydney Children's Hospital, Randwick, NSW
                   Lady Cilento Children's Hospital, Brisbane, QLD
                   Perth Children's Hospital, Perth, WA
Description: The program will involve the detailed laboratory analysis of each child’s unique cancer cells, to help identify the drugs most likely to kill their specific cancer. Scientists and doctors will then work collaboratively to identify and deliver the most effective treatment plan, specifically tailored to suit each child’s individual disease.
Contact: For more information visit, call 1800 685 686, or email

Trial Name: ACTICCA-1: Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder (ACTRN12615001283561)
Location:    Bankstown-Lidcombe Hospital, Bankstown, NSW
                    Royal Brisbane & Womens Hospital, Herston, QLD
                    Flinders Medical Centre, Bedford Park, SA
                    Nepean Hospital, Kingswood, NSW
                    Calvary Mater Newcastle, Waratah, NSW
                    The Townsville Hospital, Douglas, QLD
                    Prince of Wales Hospital, Randwick, NSW
                    Princess Alexandra Hispital, Woolloongabba, QLD
                    Sir Charles Gairdner Hospital, Nedlands, WA
Description: The trial targets patients with histologically confirmed adenocarcinoma of biliary tract (intrahepatic, hilar or extrahepatic cholangiocarcinoma or muscle invasive gallbladder carcinoma) after radical surgical therapy with macroscopically complete resection. Patients are treated with adjuvant chemotherapy with gemcitabine and cisplatin compared vs. capecitabine. It is hoped that the findings of this study will provide details on whether giving cisplatin and gemcitabine chemotherapy following surgery for cancer of the biliary tract is a safe and effective treatment to reduce the chance of disease progression and increase survival time and quality of life.
Contact: For more information contact ACTICCA-1 Trial Coordinator at

Trial Name: An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (NCT02632409)
Location:    Liverpool Hospital, Liverpool, New South Wales, Australia, 2170
                           Bavanthi Balakrishnar, 02 8738 5234      
                    Royal North Shore Hospital, St. Leonards, New South Wales, Australia, 2065
                           Alexander Guminski, 02 9463 1362      
                    Calvary Mater Newcastle, Waratah, New South Wales, Australia, 2298
                           Craig Gedye, 02 4014 3282      
                    Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia, 5112
                           Christopher Hocking, 08 8282 0833
                    St John of God Murdoch Hospital, Perth, Western Australia, Australia, 6150
                           Kynan Feeney, Site 08 9428 8556
Description: The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
Contact: For more information contact

Trial Name: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (NCT02872116)
Location:    Gosford Hospital, Gosford, New South Wales, Australia, 2250
                           Craig Kukard, 02 4320 9854      
                    Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia, 4215
                            Andrew Hill, 07 5531 4811      
                    Royal Adelaide Hospital, Adelaide, South Australia, Australia, 5000
                            Nimit Singhal, 08 8222 0087      
                    Goulburn Valley Health, Shepparton, Victoria, Australia, 3630
                            Babak Tamjid, Site 03 5832 3778      
                    St John of God Murdoch Hospital, Perth, Western Australia, Australia, 6150
                            Kynan Feeney, 08 9428 8556      
Description: The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone
Contact: For more information contact

Trial Name: A Phase I/IIa Study of the Efficacy and Safety of ASN-002 Alone or in Combination with 5-Fluoruracil (5-FU) in Adult Patients with Low-Risk Nodular Basal Cell Carcinoma (Gorlin Syndrome) (NCT02550678)
Location:    Central Brisbane Dermatology: Level 9, Silverton Place, 101 Wickham Terrace,

                            Brisbane QLD 4000, Dr Gregory Siller, 07 3831 4382
                     Q-Pharm Pty Limited: 300C Herston Road, Herston QLD 4006,       
                            Hilary Morrison, 07 3845 3657

                     St George Dermatology and Skin Cancer Centre, Kogarah, NSW, 2217
                            Sharyn Hutchinson, 02 9587 4277,
                     Sinclair Dermatology, Melbourne, Victoria, 3002, Rodney Sinclair 03 9654 2426
This research project is testing the safety and effectiveness (efficacy) of ASN-002, (an experimental treatment) alone or in combination with 5-Fluorouracil (5-FU), an anticancer chemotherapy drug. The study will also look at the changes in your BCC(s) over time, when ASN-002 alone or in-combination with 5-FU is administered directly into the BCC(s) by intra-tumoural injection. For more information, please click here
Contact: For more information contact

Trial Name: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST) (ACTRN12614000950662)
Location: Canberra Hospital, Canberra, Australian Capital Territory, Australia, 2606
                 Calvary Mater Newcastle Hospital, Newcastle, New South Wales, Australia, 2310
                 Prince of Wales Hospital, Sydney, New South Wales, Australia, 2031
                 Princess Alexandra Hospital, Brisbane, Queensland, Australia, 4120
                 Ashford Cancer Centre Research, Adelaide, South Australia, Australia, 5037
                 Flinders Medical Centre, Adelaide, South Australia, Australia, 5042
                 Royal Hobart Hospital, Hobart, Tasmania, Australia, 7001
                 Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia, 3199
                 Border Medical Oncology, Wodonga, Victoria, Australia, 3690
                 Sir Charles Gairdner, Perth, Western Australia, Australia, 6009
 An open label randomised trial for adults with histologically confirmed measurable metastatic GIST who have received no other treatment for metastatic disease. The study aims to determine if an alternating regimen of imatinib and regorafenib has sufficient activity and safety in comparison to imatinib alone to warrant further evaluation as a first line treatment for metastatic GIST.
ALT GIST Coordinator, 02 9562 5000,

Trial Name: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (NCT02899299)
Location:    Concord Repatriation General Hospital, Sydney, New South Wales, Australia, 2139,
                              Anthony Linton, +61 2976 77033
                    Birtinya, Queensland, Australia, 4575
                    Monash Medical Center Clayton, Victoria, Australia, 3168, Muhammad Alamgeer, +61 3992 88754
                    Cabrini Hospital Malvern, Victoria, Australia, 3144, Benjamin Brady, +61 3950 83421
                    Nedlands, Western Australia, Australia, 6009
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma

Trial Name: A parallel group randomised, controlled, multi-centre phase II open label trial with two cohorts testing the combination of capecitabine and temozolomide (CAPTEM) and peptide receptor radionuclide therapy (PRRT) for the treatment of advanced pancreatic or midgut neuroendocrine tumours that are not suitable for surgery.  (ACTRN12615000909527)
Location: GI Cancer Institute @ Lifehouse, Level 6, 119-143 Missenden Road, Camperdown NSW 2050

Description: The CONTROL NETS study aims to determine the activity of capecitabine + temozolomide (CAPTEM)/peptide receptor radionuclide therapy (PRRT), alone and in combination, in both pancreatic neuroendocrine tumours (pNETS) and mid-gut neuroendocrine tumours (mNETS) patients. 

Trial Name: NABNEC - A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas (ACTRN12616000958482)
Locations:       Royal North Shore Hospital, St Leonards, New South Wales
                         Westmead Hospital, Westmead, New South Wales
                         Calvary Mater Newcastle Hospital, Newcastle, New South Wales
                         Monash Medical Centre, Moorabbin, Victoria
                         Fiona Stanley Hospital, Murdoch, Western Australia
                         Royal Hobart Hospital, Hobart, Tasmania

Description: The primary purpose of this trial is to evaluate the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with carboplatin plus etoposide chemotherapy for the treatment of gastrointestinal neuroendocrine carcinomas (NECs)
Dr Mustafa Khasraw 
For further locations, additional information and contact details, please click here

Trial Name: InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease (ACTRN12616000061437)
Location: Flinders Medical Centre - Bedford Park, South Australia

Description: The purpose of the study is to compare two different chemotherapy regimens for the treatment of inoperable, locally recurrent, or metastatic anal cancer to demonstrate which is more effective and less toxic for patients with this disease. 
Dr Amitesh C Roy -
For further locations, additional information and contact details, please click here